Emcure Pharma reports 25 percent surge in profit after tax to Rs 251 crore in Q2
Pune: Emcure Pharma has posted a 25 percent surge in profit after tax (PAT) to Rs 251 crore for the quarter ended September 30, 2025.
The Pune-based drugmaker had recorded a PAT of Rs 202 crore in the same period last year.
According to the company’s statement, revenue from operations climbed to Rs 2,270 crore in the September quarter, up from Rs 2,002 crore a year ago.
The quarter saw strong performance from both Domestic and International businesses.
Domestic business grew 10.6% led by strong performance across all key therapies and aided by new initiatives. The company recently announced a strategic partnership with Novo Nordisk to launch Poviztra, biological injectable semaglutide, in India. As part of the agreement, Emcure will be the exclusive distributor responsible for the commercialization and promotion of Poviztra. Poviztra is indicated for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity. During the quarter Emcure also completed the acquisition of the minority stake in Zuventus subsidiary.
International business continues to see strong performance and grew 16%. Europe saw strong growth of 23% led by new launches and aided by Manx ramp-up. Canada continues to see robust growth and grew 18%. Rest of the World business saw sustained momentum led by non-ARV business.
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Q2 saw strong performance across all our businesses. We continue to augment our portfolio in all our focus markets though in-licensing and inhouse developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry enabling us to shape the market. We remained focus on delivering strong growth along with margin improvement in all our key businesses.”
Next Story